Core Viewpoint - The inclusion of the innovative long-acting human GLP-1 receptor agonist, Icosapent Ethyl (brand name: Yinuo Qing), in the 2025 National Medical Insurance Drug List marks a significant step towards making diabetes treatment more accessible in China, aligning with the "Healthy China 2030" initiative [1] Group 1: Company Developments - Yinuo Pharmaceutical-B (02591) saw its stock price increase by 3.43%, reaching HKD 32, with a trading volume of HKD 20.74 million [1] - The company’s product, Icosapent Ethyl, is now recognized as the first domestically developed long-acting GLP-1 receptor agonist in China [1] Group 2: Industry Impact - The inclusion of Icosapent Ethyl in the national insurance list is aimed at improving the accessibility of innovative diabetes medications [1] - The 2025 National Guidelines for Diabetes Prevention and Management highlight Icosapent Ethyl as a key treatment option for adult patients with type 2 diabetes, especially those with cardiovascular disease risk factors, heart failure, chronic kidney disease, and obesity [1]
银诺医药-B盘中涨超3% 依苏帕格鲁肽ɑ获国家基层糖尿病防治指南推荐